Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Synechocystis sp. UPF0182 protein sll1060 (sll1060), partial CSB-YP302612SSQ
CSB-EP302612SSQ
CSB-BP302612SSQ
CSB-MP302612SSQ
CSB-EP302612SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Ribonuclease HII (rnhB) CSB-YP302613SSQ
CSB-EP302613SSQ
CSB-BP302613SSQ
CSB-MP302613SSQ
CSB-EP302613SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Tyrosine recombinase XerC (xerC) CSB-YP302614SSQ
CSB-EP302614SSQ
CSB-BP302614SSQ
CSB-MP302614SSQ
CSB-EP302614SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Probable peptidyl-prolyl cis-trans isomerase sll0227 (sll0227) CSB-YP302615SSQ
CSB-EP302615SSQ
CSB-BP302615SSQ
CSB-MP302615SSQ
CSB-EP302615SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] (glmS), partial CSB-YP302616SSQ
CSB-EP302616SSQ
CSB-BP302616SSQ
CSB-MP302616SSQ
CSB-EP302616SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Carbon dioxide-concentrating mechanism protein CcmK homolog 2 (ccmK2) CSB-YP302617SSQ
CSB-BP302617SSQ
CSB-MP302617SSQ
CSB-EP302617SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. UPF0093 membrane protein slr1790 (slr1790), partial CSB-YP302618SSQ1
CSB-EP302618SSQ1
CSB-BP302618SSQ1
CSB-MP302618SSQ1
CSB-EP302618SSQ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. FO synthase subunit 2 (cofH) CSB-YP302619SSQ
CSB-EP302619SSQ
CSB-BP302619SSQ
CSB-MP302619SSQ
CSB-EP302619SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. 6-phosphofructokinase 1 (pfkA1) CSB-YP302620SSQ
CSB-EP302620SSQ
CSB-BP302620SSQ
CSB-MP302620SSQ
CSB-EP302620SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein slr0964 (slr0964), partial CSB-YP302621SSQ1
CSB-EP302621SSQ1
CSB-BP302621SSQ1
CSB-MP302621SSQ1
CSB-EP302621SSQ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein sll0925 (sll0925) CSB-YP302622SSQ
CSB-EP302622SSQ
CSB-BP302622SSQ
CSB-MP302622SSQ
CSB-EP302622SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein sll1021 (sll1021), partial CSB-YP302623SSQ1
CSB-EP302623SSQ1
CSB-BP302623SSQ1
CSB-MP302623SSQ1
CSB-EP302623SSQ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Ribosomal RNA small subunit methyltransferase B (rsmB) CSB-YP302624SSQ
CSB-EP302624SSQ
CSB-BP302624SSQ
CSB-MP302624SSQ
CSB-EP302624SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein slr1608 (slr1608) CSB-YP302625SSQ
CSB-EP302625SSQ
CSB-BP302625SSQ
CSB-MP302625SSQ
CSB-EP302625SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein slr1764 (slr1764) CSB-YP302626SSQ
CSB-EP302626SSQ
CSB-BP302626SSQ
CSB-MP302626SSQ
CSB-EP302626SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Urease subunit alpha (ureC), partial CSB-YP302627SSQ
CSB-EP302627SSQ
CSB-BP302627SSQ
CSB-MP302627SSQ
CSB-EP302627SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein slr2042 (slr2042) CSB-YP302628SSQ
CSB-EP302628SSQ
CSB-BP302628SSQ
CSB-MP302628SSQ
CSB-EP302628SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized protein slr1919 (slr1919), partial CSB-YP302629SSQ
CSB-EP302629SSQ
CSB-BP302629SSQ
CSB-MP302629SSQ
CSB-EP302629SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. S- (hydroxymethyl)glutathione dehydrogenase CSB-YP302630SSQ
CSB-EP302630SSQ
CSB-BP302630SSQ
CSB-MP302630SSQ
CSB-EP302630SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Synechocystis sp. Uncharacterized ribonuclease sll1290 (sll1290), partial CSB-YP302631SSQ
CSB-EP302631SSQ
CSB-BP302631SSQ
CSB-MP302631SSQ
CSB-EP302631SSQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶(hù)提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€(xiàn)留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>